Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age.
This report contains market size and forecasts of Polycystic Ovarian Syndrome (PCOS) Therapeutics in Global, including the following market information:
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Polycystic Ovarian Syndrome (PCOS) Therapeutics market was valued at 3848.6 million in 2021 and is projected to reach US$ 4710.4 million by 2028, at a CAGR of 2.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Contraceptive Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Polycystic Ovarian Syndrome (PCOS) Therapeutics include Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx, Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc. and Sanofi Aventis and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Polycystic Ovarian Syndrome (PCOS) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Segment Percentages, by Type, 2021 (%)
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Polycystic Ovarian Syndrome (PCOS) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Polycystic Ovarian Syndrome (PCOS) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited